Press release, 6 September 2023 at 8:30 a.m. (EEST)

Nightingale Health Plc (“Nightingale Health”), a pioneer in health risk detection and preventative health, has entered into an agreement in which Mass General Brigham orders analysis services for blood samples from Nightingale Health.

Mass General Brigham’s institutions are known for their research-infused care, and the agreement will make critical biomarker data available to researchers as they work to bring scientific findings to the healthcare setting in an effort to improve patient outcomes.

“The Mass General Brigham Biobank is a research resource at Mass General Brigham that has provided hundreds of researchers throughout our system with samples and genomic information,” said Elizabeth Karlson, MD, principal investigator of the Mass General Brigham Biobank. “The addition of these biomarker data will further support many teams that are investigating critical disease areas.”

“We are privileged to be working with Mass General Brigham and for our biomarker data to fuel research that can be translated to a clinical setting to help improve patient outcomes and transform care. Given the many publications using our data from the UK Biobank, we're extremely hopeful that Mass General Brigham scientists can make significant discoveries using the 250 Nightingale Biomarkers linked to various health aspects such as cardiometabolic disease, kidney and liver function, and immunity,” said Jeffrey Barrett, Chief Scientific Officer and Director of Research Business of Nightingale Health.

For further information, please contact:

Teemu Suna, CEO

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: